Latest Breaking News On - Late breaking clinical trial - Page 5 : comparemela.com

Janssen Submits Marketing Authorisation Application to the European Medicines Agency (EMA) Seeking Approval of Single Tablet Combination Therapy (STCT) of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)

Janssen Submits Marketing Authorisation Application to the European Medicines Agency (EMA) Seeking Approval of Single Tablet Combination Therapy (STCT) of Macitentan and Tadalafil for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomRegion flamandeTamara werner kiechleAl awawdehJanssen cilag gmbCompanies of johnsonJanssen pharmaceutical companies of johnsonJanssen research developmentNone of the janssen pharmaceutical companiesAmerican college of cardiologyJanssen pharmaceutical companiesEuropean medicines agencyWorld health organization groupExchange commissionEuropean society of cardiology respiratoryMarketing authorisation application

Cytokinetics Presents New Data in Patients With

Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and.

Czech republicUnited statesAhmad masriFadyi malikDiane weiserResearch developmentCytokinetics incorporated nasdaqNational medical products administrationInternational congressEuropean society of cardiologyExchange commissionYork heart associationUs food drug administrationCorporate communicationsStatistically significant improvementsAngina frequency

Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress

Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical. | May 20, 2023

United statesCzech republicFadyi malikAhmad masriDiane weiserCorporate communicationsUs food drug administrationHypertrophic cardiomyopathy centerYork heart associationGlobenewswire incExchange commissionOregon health science universityInternational congressEuropean society of cardiologyNational medical products administrationCytokinetics incorporated

EuroPCR 2023 | 6 Month Outcome of the SMART Study: satisfactory BP control achieved with reduced medication burden

/PRNewswire/ On May 17th 2023, the six-month result of the SMART Study (Sympathetic Mapping/Ablation Renal nerves for Treatment of hypertension Trial;.

France generalShuo yongSymap medical suzhou ltdAblation renalLate breaking clinical trialProfessor huo yongSymap medicalHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveriesOlls and research

SyMap Medical: EuroPCR 2023 | 6 Month Outcome of the SMART Study: satisfactory BP control achieved with reduced medication burden

PARIS, May 19, 2023 /PRNewswire/ On May 17th 2023, the six-month result of the SMART Study (Sympathetic Mapping/Ablation Renal nerves for Treatment of hypertension Trial; NCT02761811) was

France generalGewinn nurShuo yongSymap medical suzhou ltdAblation renalLate breaking clinical trialProfessor huo yongSymap medical